O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	19	multi
O	19	20	-
O	20	26	center
O	26	27	,
O	28	32	open
O	32	33	-
O	33	38	label
O	38	39	,
O	40	45	phase
O	46	49	III
O	50	55	study
O	56	58	of
O	59	63	once
O	63	64	-
O	64	67	per
O	67	68	-
O	68	73	cycle
B-intervention	74	76	DA
I-intervention	76	77	-
I-intervention	77	81	3031
O	81	82	,
O	83	84	a
O	85	94	pegylated
O	95	96	G
O	96	97	-
O	97	100	CSF
O	100	101	,
O	102	104	in
O	105	115	comparison
O	116	120	with
O	121	126	daily
B-control	127	137	filgrastim
O	138	140	in
B-eligibility	141	149	patients
I-eligibility	150	159	receiving
I-eligibility	160	163	TAC
I-eligibility	164	176	chemotherapy
I-eligibility	177	180	for
I-eligibility	181	187	breast
I-eligibility	188	194	cancer
O	194	195	.

O	196	200	This
O	201	206	multi
O	206	207	-
O	207	213	center
O	213	214	,
O	215	225	randomized
O	225	226	,
O	227	232	phase
O	233	236	III
O	237	242	study
O	243	246	was
O	247	256	conducted
O	257	259	to
O	260	271	demonstrate
O	272	275	the
O	276	279	non
O	279	280	-
O	280	291	inferiority
O	292	294	of
O	295	297	DA
O	297	298	-
O	298	302	3031
O	303	311	compared
O	312	316	with
O	317	322	daily
O	323	333	filgrastim
O	334	336	in
O	337	345	patients
O	346	352	during
O	353	356	the
O	357	362	first
O	363	368	cycle
O	369	371	of
O	372	384	chemotherapy
O	385	388	for
O	389	395	breast
O	396	402	cancer
O	403	405	in
O	406	411	terms
O	412	414	of
O	415	418	the
O	419	427	duration
O	428	430	of
O	431	437	severe
O	438	449	neutropenia
O	450	451	(
O	451	454	DSN
O	454	455	)
O	455	456	.

B-total-participants	457	464	Seventy
I-total-participants	464	465	-
I-total-participants	465	469	four
B-eligibility	470	478	patients
I-eligibility	479	483	with
I-eligibility	484	490	breast
I-eligibility	491	497	cancer
I-eligibility	498	501	who
I-eligibility	502	506	were
I-eligibility	507	516	receiving
I-eligibility	517	528	combination
I-eligibility	529	541	chemotherapy
I-eligibility	542	546	with
I-eligibility	547	556	docetaxel
I-eligibility	556	557	,
I-eligibility	558	569	doxorubicin
I-eligibility	569	570	,
I-eligibility	571	574	and
I-eligibility	575	591	cyclophosphamide
I-eligibility	592	593	(
I-eligibility	593	596	TAC
I-eligibility	596	597	)
O	598	602	were
O	603	611	enrolled
O	611	612	.

O	613	616	All
O	617	629	participants
O	630	634	were
O	635	645	randomized
O	646	648	to
O	649	656	receive
O	657	663	either
O	664	669	daily
O	670	682	subcutaneous
O	683	693	injections
O	694	696	of
O	697	707	filgrastim
O	708	711	100
O	712	713	μ
O	713	714	g
O	714	715	/
O	715	717	m2
O	717	718	/
O	718	721	day
O	722	725	for
O	726	728	up
O	729	731	to
O	732	734	10
O	735	739	days
O	740	742	or
O	743	744	a
O	745	751	single
O	752	764	subcutaneous
O	765	774	injection
O	775	777	of
O	778	780	DA
O	780	781	-
O	781	785	3031
O	786	788	at
O	789	794	fixed
O	795	800	doses
O	801	803	of
O	804	805	6
O	806	808	mg
O	809	811	on
O	812	815	day
O	816	817	2
O	818	820	of
O	821	825	each
O	826	838	chemotherapy
O	839	844	cycle
O	844	845	.

O	846	849	The
B-outcome	850	854	mean
I-outcome	855	863	duration
I-outcome	864	866	of
I-outcome	867	872	grade
I-outcome	873	874	4
I-outcome	875	876	(
I-outcome	876	878	G4
I-outcome	878	879	)
I-outcome	880	891	neutropenia
I-outcome	892	894	in
I-outcome	895	900	cycle
I-outcome	901	902	1
O	903	906	was
B-cv-cont-mean	907	908	2
I-cv-cont-mean	908	909	.
I-cv-cont-mean	909	911	08
O	912	913	±
B-cv-cont-sd	914	915	0
I-cv-cont-sd	915	916	.
I-cv-cont-sd	916	918	85
I-cv-cont-sd	919	923	days
O	924	927	for
O	928	931	the
O	932	942	filgrastim
O	943	948	group
O	949	952	and
B-iv-cont-mean	953	954	2
I-iv-cont-mean	954	955	.
I-iv-cont-mean	955	957	28
O	958	959	±
B-iv-cont-sd	960	961	1
I-iv-cont-sd	961	962	.
I-iv-cont-sd	962	964	14
I-iv-cont-sd	965	969	days
O	970	973	for
O	974	977	the
O	978	980	DA
O	980	981	-
O	981	985	3031
O	986	991	group
O	991	992	.

O	993	996	The
O	997	1007	difference
O	1008	1015	between
O	1016	1022	groups
O	1023	1026	was
O	1027	1028	0
O	1028	1029	.
O	1029	1030	2
O	1031	1032	±
O	1033	1034	1
O	1034	1035	.
O	1035	1037	10
O	1038	1042	days
O	1043	1044	(
O	1044	1046	95
O	1047	1048	%
O	1049	1059	confidence
O	1060	1068	interval
O	1069	1070	(
O	1070	1072	CI
O	1072	1073	)
O	1074	1075	=
O	1076	1077	-
O	1077	1078	0
O	1078	1079	.
O	1079	1081	26
O	1081	1082	,
O	1083	1084	0
O	1084	1085	.
O	1085	1087	66
O	1087	1088	)
O	1088	1089	,
O	1090	1095	which
O	1096	1105	supported
O	1106	1109	non
O	1109	1110	-
O	1110	1121	inferiority
O	1121	1122	.

O	1123	1125	No
O	1126	1139	statistically
O	1140	1151	significant
O	1152	1163	differences
O	1164	1168	were
O	1169	1177	observed
O	1178	1180	in
B-outcome	1181	1186	nadir
I-outcome	1187	1195	absolute
I-outcome	1196	1206	neutrophil
I-outcome	1207	1212	count
I-outcome	1213	1214	(
I-outcome	1214	1217	ANC
I-outcome	1217	1218	)
O	1219	1220	(
B-cv-cont-mean	1220	1223	154
I-cv-cont-mean	1223	1224	.
I-cv-cont-mean	1224	1226	34
I-cv-cont-mean	1226	1227	/
I-cv-cont-mean	1227	1230	mm3
O	1231	1234	and
B-iv-cont-mean	1235	1238	161
I-iv-cont-mean	1238	1239	.
I-iv-cont-mean	1239	1241	75
I-iv-cont-mean	1241	1242	/
I-iv-cont-mean	1242	1245	mm3
O	1246	1249	for
O	1250	1253	the
O	1254	1264	filgrastim
O	1265	1268	and
O	1269	1271	DA
O	1271	1272	-
O	1272	1276	3031
O	1277	1283	groups
O	1283	1284	,
O	1285	1297	respectively
O	1297	1298	;
O	1299	1300	P
O	1301	1302	=
O	1303	1304	0
O	1304	1305	.
O	1305	1309	8414
O	1309	1310	)
O	1311	1313	or
O	1314	1316	in
B-outcome	1317	1321	time
I-outcome	1322	1324	to
I-outcome	1325	1328	ANC
I-outcome	1329	1337	recovery
O	1338	1339	(
B-cv-cont-mean	1339	1341	10
I-cv-cont-mean	1341	1342	.
I-cv-cont-mean	1342	1344	03
O	1345	1346	±
B-cv-cont-sd	1347	1348	0
I-cv-cont-sd	1348	1349	.
I-cv-cont-sd	1349	1351	75
O	1352	1355	and
B-iv-cont-mean	1356	1357	9
I-iv-cont-mean	1357	1358	.
I-iv-cont-mean	1358	1360	83
O	1361	1362	±
B-iv-cont-sd	1363	1364	1
I-iv-cont-sd	1364	1365	.
I-iv-cont-sd	1365	1367	56
I-iv-cont-sd	1368	1372	days
O	1373	1375	in
O	1376	1379	the
O	1380	1390	filgrastim
O	1391	1394	and
O	1395	1397	DA
O	1397	1398	-
O	1398	1402	3031
O	1403	1409	groups
O	1409	1410	,
O	1411	1423	respectively
O	1423	1424	;
O	1425	1426	P
O	1427	1428	=
O	1429	1430	0
O	1430	1431	.
O	1431	1435	0611
O	1435	1436	)
O	1437	1443	during
O	1444	1449	cycle
O	1450	1451	1
O	1451	1452	.

B-outcome	1453	1460	Serious
I-outcome	1461	1464	AEs
O	1465	1473	occurred
O	1474	1476	in
B-cv-bin-abs	1477	1480	six
O	1481	1482	(
B-cv-bin-percent	1482	1484	15
I-cv-bin-percent	1484	1485	.
I-cv-bin-percent	1485	1486	8
I-cv-bin-percent	1487	1488	%
O	1488	1489	)
O	1490	1498	patients
O	1499	1508	receiving
O	1509	1519	filgrastim
O	1520	1523	and
O	1524	1526	in
B-iv-bin-abs	1527	1530	ten
O	1531	1532	(
B-iv-bin-percent	1532	1534	27
I-iv-bin-percent	1534	1535	.
I-iv-bin-percent	1535	1536	8
I-iv-bin-percent	1537	1538	%
O	1538	1539	)
O	1540	1548	patients
O	1549	1558	receiving
O	1559	1561	DA
O	1561	1562	-
O	1562	1566	3031
O	1566	1567	;
O	1568	1575	however
O	1575	1576	,
O	1577	1581	none
O	1582	1585	was
O	1586	1596	determined
O	1597	1599	to
O	1600	1602	be
O	1603	1610	related
O	1611	1613	to
O	1614	1617	the
O	1618	1623	study
O	1624	1628	drug
O	1628	1629	.

O	1630	1632	DA
O	1632	1633	-
O	1633	1637	3031
O	1638	1641	and
O	1642	1647	daily
O	1648	1658	filgrastim
O	1659	1662	are
O	1663	1670	similar
O	1671	1673	in
O	1674	1680	regard
O	1681	1683	to
O	1684	1687	DSN
O	1688	1691	and
O	1692	1698	safety
O	1699	1701	in
O	1702	1708	breast
O	1709	1715	cancer
O	1716	1724	patients
O	1725	1734	receiving
O	1735	1738	TAC
O	1739	1751	chemotherapy
O	1751	1752	.
